Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin for olanzapine-associated metabolic abnormalities in schizophrenia
IRCT20191210045677N1Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in schizophrenia comparing Olanzapine + sitagliptin with Olanzapine + placebo (2 arms). Primary endpoints: Body mass index, Waist circumference and 3 more. Started Dec 2019; status: completed.
02
Drugs
sitagliptinolanzapine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on IRCT20191210045677N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191210045677N1.